Indeed, the use of selective A2A or A3 receptor agonists showed beneficial effects in counteracting the inflammatory burst in murine models of colitis, acting on both the innate and acquired component of the immune system (82–85). This evidence concerns the gene IGKV2D-29 and colitis.